Viewing 0 reply threads
  • Author
    Posts
    • #17624

      Larimar issued a press release to discuss the topline data from its Phase 1 multiple ascending dose (MAD) clinical trial (n=27) evaluating CTI-1601 as a treatment for FA in a call this morning at 8am (ET). Data show that repeated subcutaneous administration of CTI-1601 resulted in dose-dependent increases in frataxin (FXN) levels from baseline compared to placebo controls. These dose-dependent increases in frataxin levels were seen in all evaluated tissues with daily dosing.

      The company anticipates initiation of an open-label extension clinical trial for patients who completed the single ascending dose (SAD) and/or MAD clinical trials in the second half of 2021. Larimar also expects to initiate a MAD clinical trial in patients under 18 years of age in the second half of 2021.

      To read the full press release or for information on how to join the call, visit: https://investors.larimartx.com/news-releases/news-release-details/larimar-therapeutics-reports-positive-topline-phase-1-clinical

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2021 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account